Another PPARα antagonist, NXT629, inhibited the enlargement of chronic lymphocytic leukemia and ovarian cancer in a mouse model, and only NXT629 administration immediately after transplantation exhibited anti-tumor effects in a B16F10 melanoma subcutaneous transplantation model [45,46]. This evidence concerns the gene PPARA and melanoma.